falsefalse

Optimizing Biomarker Testing in Your Practice: Leveraging In-House Testing Strategies - Episode 3

When to Choose Narrow Panel Testing Over Comprehensive Testing in Biomarker Analysis

,

Panelists discuss how comprehensive genomic testing may not be practical for well-understood tumors with established treatment pathways. Narrow panel testing is preferred when specific mutations guide therapy (like EGFR in lung cancer) or when time/cost constraints exist.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video series above is prompted by the following:

    • Are there scenarios where comprehensive testing might be unnecessary or less practical (certain tumor types)?
    • In which scenarios might you prefer narrow panel testing over comprehensive testing?
    x